If you started semaglutide and stopped sleeping well, the first thing worth knowing is that insomnia is not a labeled side effect.
That does not mean nothing is happening. It means the trials did not find it, so the cause is worth looking for somewhere else.
This page walks the label first, then the safety databases, then what happens to sleep on treatment. The full label picture is in semaglutide side effects.
What the label says
The Wegovy label, revised June 2026, does not use the word insomnia anywhere [1]. Neither does the Ozempic label, revised May 2026 [2].
What the label does record is fatigue. In the pooled adult weight trials, 11% on Wegovy 2.4 mg reported it against 5% on placebo [1].
The denominators there are 2,116 on the drug and 1,261 on placebo. The label footnotes that row as covering both fatigue and asthenia.
At the higher dose the figures were 5% on placebo, 9% on 2.4 mg and 11% on 7.2 mg. Fatigue is not insomnia, but the two get reported together by patients.
What the safety databases show
Two large analyses have searched adverse-event reports for psychiatric signals across this drug class.
The first read 181,238 reports in FDA's reporting system, of which 8,240 were psychiatric [3]. The only insomnia-shaped term it flagged was fear of injection, insomnia type, at a reporting odds ratio of 2.01 (95% CI 1.60 to 2.52).
The second compared US, Canadian and Australian databases [4]. It found an insomnia signal for dulaglutide, at a reporting odds ratio of 2.93 (95% CI 2.35 to 3.66), and not for semaglutide.
Semaglutide's own signals in that analysis were depressive symptoms and suicidal ideation, at a reporting odds ratio of 2.58 (95% CI 2.31 to 2.88). Those are reports, not rates, and they cannot tell you how often anything happens.
A study built to answer the rate question used matched health records instead [5]. It compared 23,386 people on semaglutide with a matched group on sitagliptin, and smaller matched groups against empagliflozin and glipizide.
Insomnia was one of its 22 prespecified outcomes over 12 months. Semaglutide was not associated with an increased risk of any of them.
What actually happens to sleep
The studies that measured sleep directly found it improving, not worsening.
| Study | Who | What it measured | Result |
|---|---|---|---|
| Kır 2026 | 78 adults with obesity starting semaglutide or tirzepatide | Pittsburgh Sleep Quality Index at 3 months | Median score 6.0 to 3.0; poor sleep 55.1% to 16.7% |
| SCALE Sleep Apnea, 2016 | Adults with obesity and moderate or severe sleep apnea | Apnea-hypopnea index at 32 weeks, liraglutide 3.0 mg | Down 12.2 events per hour vs 6.1 on placebo |
| SURMOUNT-OSA, 2024 | Adults with obesity and moderate-to-severe sleep apnea | Apnea-hypopnea index at 52 weeks, tirzepatide | Down 25.3 events per hour vs 5.3 on placebo |
The first is a real-world study of 78 people, 26 of them on semaglutide [6]. Median sleep scores improved and the share sleeping badly fell from 55.1% to 16.7%, both at P < 0.001.
It has no control group, so some of that is regression and expectation. It still points away from a drug that wrecks sleep.
The sleep apnea trials are stronger. Liraglutide 3.0 mg cut the apnea-hypopnea index by 12.2 events per hour against 6.1 on placebo [7]. That is a treatment difference of −6.1 (95% CI −11.0 to −1.2, P = 0.0150).
Tirzepatide did much more: 25.3 events per hour against 5.3, a treatment difference of −20.0 (95% CI −25.8 to −14.2, P < 0.001) [8]. That trial is covered in Zepbound and sleep apnea.
What to ask, and in what order
Start with the things the label does name. Ask whether nausea, reflux or an evening dose is what is waking you.
Then ask about timing. The injection day and the hours you eat both move around when treatment starts.
If you take insulin or a sulfonylurea, ask about overnight lows. That is a labeled interaction, not a speculation.
And ask whether anything else changed at the same time. A new dose step, a new routine and a new medicine often arrive together.
None of that is a reason to start or stop anything on your own. It is the order a prescriber can work through with you.
Putting it together
On the evidence available, semaglutide is not an insomnia drug. The labels do not name it, no randomized trial has measured it, and the one large matched cohort that looked for it found nothing.
What is documented is fatigue, and gut symptoms that can interrupt a night. If your sleep changed, those are the first places to look.
For which peptides have actually been tested for sleep, see peptides for sleep. For a symptom with the same shape and a clearer label answer, see semaglutide headache, and for the rest of this goal, the sleep hub.
To compare prescribers by what a month costs, see the compounded semaglutide rankings.